Drug Development Institute


OSUCCC – JAMES DRUG DEVELOPMENT INSTITUTE (DDI)
Accelerating drug discovery and development through collaboration and results-based project management to speed new cancer treatments to patients

Drug Development Partners
• The Ohio State University Comprehensive Cancer Center – world-class cancer research expertise and intellectual property
• The Ohio State University – breadth of resources expected from one of the nation’s largest public universities
• R&D Industry – global experience and expertise in innovation development and commercialization
• Pharmaceutical Industry – global experience and expertise in pharmaceutical cancer drug development and commercialization

Core Strategies
• Create and optimize the value of Ohio State’s cancer research and develop a viable pipeline
• Prioritize high-value projects and accelerate compounds through pre-clinical development
• Drive results using a milestone-based project management system
• Acquire funding for the most promising early-stage projects
• Formalize meaningful strategic alliances with internal and external partners
• Augment resources for continued investment in research

Process
• Identify promising drugs or compounds in the early stages of discovery and development
• Analyze and determine viability of compound as a commercial product
• Optimize value of compound by collaborating with university resources and industry partners
• Utilize DDI’s proprietary project management system to:
    - Create rigorous project plans to guide researchers
    - Ensure data integrity
• Manage project plans in three ways: DDI managed, partnered or out-licensed
• Execute plan through phase I or selected phase II clinical trials
• Efficiently propel discoveries forward with periodic internal and external advisory board reviews

Results
Ohio State’s Drug Development Institute utilizes a unique, proven approach to identify promising compounds created by Ohio State cancer research experts, recognizes and optimizes the value of those compounds, and leverages alliances with partners within the university and throughout the global industry to help deliver cancer drugs, and ultimately cures, to patients faster.

DDI Leadership


Tim Wright

Founding Partner and Director
Tim Wright has nearly 30 years of global pharma and biotech leadership experience, holding some of the highest posts, including board of director positions. Mr. Wright has comprehensive operating, drug-development, regulatory and strategic-management expertise, including small molecule, peptide and protein development.



Bence Boelcskevy, PhD

Partner and Deputy Director
Dr. Boelcskevy has more than 32 years of pharma industry experience in R&D, project management, clinical operations, quality assurance and manufacturing operations. He has rationalized development portfolios, implementing a system that resulted in a 90+% critical milestone completion rate, and led cross-functional teams through the complex development and commercialization processes.


Contact for Additional Information
Bence Boelcskevy, PhD
614-685-5668
bence.boelcskevy@osumc.edu

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu